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Activation of nuclear factor-kB (NF-kB) signaling was observed in pancreatic adenocarcinoma cell lines and tumours. However,
information on the expression of RelA/p65, the major transcription activating NF-kB subunit, in these carcinomas and possible
correlations thereof with NF-kB activation and patient survival is not available. To provide this missing translational link, we analysed
expression of RelA/p65 in 82 pancreatic adenocarcinomas by immunohistochemistry. Moreover, we measured activation of the
NF-kB pathway in 11 tumours by quantitative PCR for NF-kB target genes. We observed strong cytoplasmic or nuclear expression
of RelA/p65 in 42 and 37 carcinomas, respectively. High cytoplasmic and nuclear expression of RelA/p65 had negative prognostic
impact with 2-year survival rates for patients without cytoplasmic or nuclear RelA/p65 positivity of 41 and 40% and rates for patients
with strong cytoplasmic or nuclear RelA/p65 expression of 22 and 20%, respectively. High RelA/p65 expression was correlated to
increased expression of NF-kB target genes. The observation that high expression of RelA/p65 is correlated to an activation of the
NF-kB pathway and indicates poor patient survival identifies a patient subgroup that might particularly benefit from NF-kB-inhibiting
agents in the treatment of pancreatic cancer. Based on our findings, this subgroup could be identified by applying simple
immunohistochemical techniques.
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Pancreatic carcinoma is one of the most aggressive of all cancer
types, in which the mortality rate almost equals the rate of incidence
(Jemal et al, 2006). The clinically silent onset and the lack of an
effective therapy for advanced stage tumours contribute substan-
tially to the deleterious 5-year survival rate of less than 5%
(Mimeault et al, 2005). Only few pancreatic carcinomas are detected
early enough to allow curative treatment. Current chemotherapeutic
regimens are ineffective and do not prolong patient survival
significantly (Haller, 2003). This explains the urgent necessity to
identify the molecular alterations in pancreatic carcinomas in order
to develop new treatment strategies for this neoplasm.
The transcription factor NF-kB is involved in inflammatory and
innate immune responses (Li and Verma, 2002). It is assembled as
a hetero- or homodimer from the structurally closely related
subunits RelA/p65, c-Rel, RelB, p50 and p52 (Karin et al, 2002).
Nuclear factor-kB is sequestered and inactivated in the cytoplasm
by binding to one of the specific inhibitors, IkBa, b or e. Upon
phosphorylation of the inhibitor by IkB kinase (IKK), NF-kBi s
released, translocates into the nucleus and binds to kB sites in the
promoters of target genes to exert its transcriptional activity
(Karin et al, 2004). Deregulated IKK and NF-kB activity contribute
to tumorigenesis by triggering antiapoptotic and proproliferative
responses (Rayet and Gelinas, 1999; Baldwin, 2001). Furthermore,
activation of IKK and NF-kB may play an important role in cancer
progression elicited by inflammatory cytokines (Karin and Greten,
2005).
Increasing evidence for an involvement of NF-kB in pancreatic
cancer has accumulated in the last several years (Algu ¨l et al, 2002;
Sclabas et al, 2003), which is not surprising given the fact that
inflammatory mechanisms contribute to the genesis of this disease
(Farrow and Evers, 2002). Using electrophoretic mobility shift
assays comparing extracts from tumours and adjacent normal
tissue, Wang et al (1999) demonstrated an activation of NF-kBi n
pancreatic cancers. Furthermore, they profiled a small set of
pancreatic tumours immunohistochemically and detected nuclear
RelA. In another study, NF-kB was found to be activated in a
number of pancreatic cancer cell lines, which was later linked to
chemotherapy resistance (Arlt et al, 2001, 2003). Consequently,
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sinhibition of NF-kB activation in these cell lines using sulfasalazine
or the proteasome inhibitor MG-132 resulted in their sensitisation
to etoposide, doxorubicin (Arlt et al, 2001) and gemcitabine (Arlt
et al, 2003). More recently, overexpression of several NF-kB
subunits was described in the cytoplasm as well as in the nucleus
of the pancreatic adenocarcinoma cell lines Panc-1 and BxPC-3
(Chandler et al, 2004). Nevertheless, a unanimous link between the
overexpression of NF-kB subunits and NF-kB activity in these cell
lines could not be established so far.
We determined expression of the NF-kB subunit RelA/p65 in
normal pancreas parenchyma, in chronic pancreatitis, in pancrea-
tic intraepithelial neoplasia (PanIN) and in invasive pancreatic
carcinoma and correlated the expression patterns to clinicopatho-
logical tumour characteristics. Additionally, we clarified if altered
RelA expression was associated with changes in NF-kB activity in
vivo by measuring expression of NF-kB-regulated genes in a subset
of pancreatic carcinomas.
MATERIALS AND METHODS
Patient characteristics
Tissue samples from 87 patients who underwent partial pancrea-
ticoduodenectomy for either primary pancreatic adenocarcinoma
(82 cases) or chronic pancreatitis (5 cases) at the Charite ´
University Hospital between 1991 and 2000 were used in this
study (Table 1). Median age of patients with pancreatic cancer was
65 years (range 39–80 years). Follow-up data were available for all
patients. Within the follow-up time, 65 patients (79.3%) died after
a median follow-up time of 11.5 months. Median follow-up time of
patients still alive at the end point of analysis was 44.0 months.
Immunohistochemistry
A well-characterised monoclonal RelA-antibody (sc-8008, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was used on 5mm
paraffin sections (Higashitsuji et al, 2002; Ross et al, 2004). After
heat-induced antigen retrieval, slides were incubated with primary
antibody (1:250) at 41C overnight. Bound antibody was detected
by a streptavidin–biotin system (BioGenex, San Ramon, CA,
USA). For colour development, a Fast Red system (Sigma,
Deisenhofen, Germany) was used. The slides were cover slipped
after counterstaining.
Evaluation of staining of tissue slides
Cytoplasmic as well as nuclear RelA staining was scored by
applying a semiquantitative immunoreactivity scoring (IRS)
system, which ranges from 0 to 12, as described (Weichert et al,
2004). For statistical analysis, cases exhibiting an IRS from 0 to 6
were considered as RelA ‘negative’, cases with an IRS of 8 or higher
were considered as RelA ‘positive’. Cases were grouped as nuclear-
positive if distinct expression of RelA in the nuclei of tumour cells
(IRS40) could be discerned.
RNA extraction from paraffin-embedded tumour tissue
From the whole study cohort of 82 carcinomas those cases were
selected for which tumour tissue blocks without normal pancreatic
Table 1 Distribution of clinicopathological characteristics in the study cohort and correlation with cytoplasmic and nuclear RelA expression
All cases
RelA cytoplasmic
negative
RelA cytoplasmic
positive P-values
RelA nuclear
negative
RelA nuclear
positive P-values
All cases 82 40 (48.8%) 42 (51.2%) 45 (54.9%) 37 (45.1%)
Age (years)
p65 42 (51.2%) 20 (47.6%) 22 (52.4%) 1.000
a 23 (54.8%) 19 (45.2%) 1.000
a
465 40 (48.8%) 20 (50%) 20 (50%) 22 (55%) 18 (45%)
Tumour stage
T1 1 (1.2%) 1 (100%) 0 (0%) 0.062
b 1 (100%) 0 (0%) 0.050
b
T2 30 (36.6%) 17 (56.7%) 13 (43.3%) 19 (63.3%) 11 (36.7%)
T3 48 (58.5%) 22 (45.8%) 26 (54.2%) 25 (52.1%) 23 (47.9%)
T4 3 (3.7%) 0 (0%) 3 (100%) 0 (0%) 3 (100%)
Nodal status
N0 26 (31.7%) 17 (65.4%) 9 (34.6%) 0.057
a 18 (69.2%) 8 (30.8%) 0.097
a
N1 56 (68.3%) 23 (41.1%) 33 (58.9%) 27 (48.2%) 29 (51.8%)
Lymph vessel invasion
L0 54 (65.9%) 22 (40.7%) 32 (59.3%) 0.062
a 28 (51.9%) 26 (48.1%) 0.490
a
L1 28 (34.1%) 18 (64.3%) 10 (35.7%) 17 (60.7%) 11 (39.3%)
Blood vessel invasion
V0 71 (86.6%) 34 (47.9%) 37 (52.1%) 0.753
a 39 (54.9%) 32 (45.1%) 1.000
a
V1 11 (13.4%) 6 (54.5%) 5 (45.5%) 6 (54.5%) 5 (45.5%)
Grade
G1 8 (9.8%) 2 (25%) 6 (75%) 0.939
b 4 (50%) 4 (50%) 0.205
b
G2 43 (52.4%) 25 (58.1%) 18 (41.9%) 28 (65.1%) 15 (34.9%)
G3 31 (37.8%) 13 (41.9%) 18 (58.1%) 13 (41.9%) 18 (58.1%)
RelA nuclear
Negative 45 (54.9%) 33 (73.3%) 12 (26.7%) o0.001
a ——
Positive 37 (45.1%) 7 (18.9%) 30 (81.1%) — —
aFisher’s exact test.
bw
2 test for trends.
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sparenchyma, lymph node parenchyma and duodenal wall were
available. In addition, the tumour tissue blocks selected must
contain at least 70% of pure carcinoma tissue, the remaining up to
30% consisting only of fat and/or connective tissue. To rule out a
significant bias by variations in the density of inflammatory
infiltrates, the amount of granulocytes, lymphocytes and desmo-
plastic stroma reaction were scored on H&E slides. None of these
parameters correlated with expression of any of the genes
investigated (data not shown).
The strict selection criterions were fulfilled by only 11 out of our
82 cases. From these cases, 10mm-thick paraffin sections were cut
from the tissue blocks and RNA was isolated using a High Pure
RNA Paraffin Kit (Roche, Mannheim, Germany). Briefly, after
deparaffinisation using xylene, the tissue was homogenised by an
overnight incubation with proteinase K and the nucleic acids were
purified via spin-columns. Subsequently, residual DNA was
digested by DNAse treatment.
Quantitative PCR
One microgram of total RNA was reverse transcribed using
AMV reverse transcriptase from Roche. Quantitative real-time
PCR (TaqMant) using Assay on Demand (number given in
parentheses) from Applied Biosystems (Darmstadt, Germany)
was employed to quantify the expression of RELA (Hs00153294_m1),
NFKBIA (Hs00153283_m1), CCND2 (Hs00153380_m1), GAPDH
(Hs99999905_m1), GUSB (Hs99999908_m1), B2M (Hs99999907_m1)
and RPLPO (Hs99999902_m1) from cDNA samples. BCL2L1 and
CCND1 expression was evaluated using the primers TGGAACTC
TATGGGAACAATGCA (forward)/TCAGGAACCAGCGGTTGAAG
(reverse) and TCGTGGCCTCTAAGATGAAGGA (forward)/GATG
GAGCCGTCGGTGTAGAT (reverse), respectively. All PCRs were
performed in triplicates in a 25-ml reaction volume containing
2.5ml of total cDNA on an ABI Prism 7900 HT Sequence Detection
System and using the following PCR conditions: 2min at 501C,
10min at 951C, followed by 40 cycles of 951C for 10s and 601C for
1min. Ct values of RELA and NF-kB target genes were
standardised to the average of the Ct values of the four reference
genes GAPDH, GUSB, B2M and RPLPO to obtain DCt values for
their relative expression.
Statistical analysis
Statistical analyses were performed using SPSS 12.0 and GraphPad
Prism 4.0. Fisher’s exact test and w
2 test for trends, Kaplan–Meier
curves (log-rank test) and Cox regression were applied. Two-year
survival rates were extracted from Kaplan–Meier survival tables.
Differences in mRNA gene expression in dependence of nuclear
RelA protein expression were checked with a t-test. Correlation of
qPCR data for gene expression was performed by Pearson
correlation and linear regression analyses. For correlation analyses
involving RELA expression, two outlier samples were omitted, thus
reducing the total sample size to nine.
RESULTS
Expression patterns of RelA in non-neoplastic pancreatic
tissue
Normal acinar pancreas parenchyma as well as non-transformed
ductal epithelium showed weak cytoplasmic positivity but no
nuclear expression of RelA (Figure 1A). Smooth muscle cells of
vessel walls and duodenal walls were weakly positive for RelA in
the cytoplasm and nuclei (Figure 1C). Occasionally, RelA
expression could be observed in the nuclei of stromal cells.
Inflammatory infiltrate in both non-neoplastic and tumour tissue
partially exhibited both strong cytoplasmic and nuclear staining
(Figure 1D).
Ductular proliferates in chronic pancreatitis showed an elevated
cytoplasmic expression of RelA when compared to unaffected
parenchyma, with four out of six cases scoring as cytoplasmic
positive for RelA. In addition, in three of the five cases
investigated, occasional nuclear RelA staining was observed
(Figure 1B).
Expression patterns of RelA in ductal pancreatic
adenocarcinoma
Cytoplasmic and nuclear overexpression of RelA was evident in a
subset of pancreatic adenocarcinomas. However, the extent of
overexpression in the majority of cases was not homogenous
throughout the tissue, with some tumours exhibiting strong
expression in certain clusters of tumour cells while other tumour
areas displayed only weak positivity. Forty-two out of 82
adenocarcinomas (51.2%) showed cytoplasmic overexpression in
neoplastic ducts (Figure 1D and E), the remaining cases were RelA-
negative (Figure 1C). Additionally, 37 (45.1%) pancreatic carcino-
mas revealed a distinct nuclear positivity (Figure 1E). Thirty out of
the 42 (81.1%) cases with cytoplasmic overexpression revealed
nuclear overexpression as well (Po0.001) (Table 1). Cytoplasmic
RelA overexpression was observed in high-grade pancreatic
AB
CD
EF
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50 m 100 m
Figure 1 RelA/p65 expression in pancreatic tissue. (A) Weak
cytoplasmic RelA expression in pancreatic acinar parenchyma and in
pancreatic ducts (arrows). (B) Ductular proliferates in chronic pancreatitis
with weak cytoplasmic but focal nuclear (arrows) RelA expression. Inset:
Higher magnification of one duct with nuclear RelA positivity. (C) Ductal
adenocarcinoma (arrows) with weak cytoplasmic RelA expression. Note
smooth muscle cells in the tumour vicinity exhibiting nuclear RelA positivity
(arrowheads). (D) Ductal adenocarcinoma (arrows) with moderate
cytoplasmic but no nuclear RelA expression. Note strong cytoplasmic
and nuclear RelA positivity in adjacent inflammatory cells (arrowheads). (E)
Ductal adenocarcinoma with strong cytoplasmic and nuclear (arrows)
expression of RelA. (F) PanIN III with strong cytoplasmic positivity for RelA
(arrowheads). Note an invasive gland in the vicinity (arrow).
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sintraepithelial neoplasia (PanIN III), in the vicinity of invasive
tumour (Figure 1F). Mesenchymal cells of desmoplastic tumour
stroma exhibited nuclear RelA expression in a minority of cells
as well.
Correlation of cytoplasmic and nuclear RelA
overexpression with clinicopathological factors and
survival
Neither cytoplasmic nor nuclear expression patterns of RelA
showed a statistically significant correlation with age and grade of
differentiation (Table 1). Concerning tumour stage and nodal
status, a strong trend towards higher cytoplasmic and nuclear RelA
expression levels was observed for locally more advanced and
nodal-positive tumours (Table 1).
Regarding patient survival, high cytoplasmic as well as high
nuclear expression of RelA was significantly associated with
decreased survival time (Table 2 and Figure 2). Patients with
cytoplasmic negativity for RelA in the tumour survived for a
median time of 16.3 month as opposed to a median survival time
of 13.3 month in the group of patients whose tumours showed high
RelA expression in the cytoplasm (P¼0.034; Table 2 and Figure 2).
In the group of patients with nuclear RelA positivity, the median
survival time was lowered to 13.1 months compared to 17.7
months median survival for those patients without nuclear RelA
expression (P¼0.013; Table 2 and Figure 2). The estimated 2-year
survival rates for patients without cytoplasmic or nuclear RelA
positivity were 41 and 40%, while 2-year survival rates for patients
with strong cytoplasmic or nuclear RelA expression were 22 and
20%, respectively. These survival differences were even more
pronounced in the subgroup of node-negative patients showing a
survival advantage for patients without cytoplasmic RelA expres-
sion (n¼17, median survival time not reached) compared to
patients with high cytoplasmic RelA expression (n¼9, median
survival time: 12.0 months) (P¼0.005; Table 2 and Figure 2). For
nuclear RelA, in this subgroup, median survival of patients with
positivity in the tumour was reduced to 10.1 months while the
median survival time was not reached in the remaining patients
without nuclear RelA overexpression (P¼0.023, Table 2). In
multivariate survival analyses of the whole study cohort with
inclusion of nodal status, grade and alternatively cytoplasmic or
nuclear RelA expression, no independent prognostic impact of
RelA positivity was observed (cytoplasmic: P¼0.235, nuclear:
P¼0.120). However, in the subgroup of nodal-negative cases
(n¼26) an exploratory multivariate survival analysis with
inclusion of grade and cytoplasmic RelA positivity showed RelA
overexpression as a significant prognosticator (relative risk¼3.49,
P¼0.020). Likewise, a similar trend was observed for nuclear
positivity (P¼0.079).
Correlation of RelA expression with NF-jB target gene
mRNA expression
In the subset of tumours suited for quantitative PCR analyses, we
profiled the mRNA expression of RELA (encoding for RelA/p65)
and a number of NF-kB target genes, such as BCL2L1 (Bcl-xL),
CCND1 (Cyclin D1), CCND2 (Cyclin D2) and NFKBIA (IkBa).
Since NFKBIA transcription is assumed to be almost exclusively
regulated by NF-kB and its mRNA is also very rapidly degraded,
NFKBIA has been proposed as a good surrogate marker for NF-kB
transcriptional activity (Emmerich et al, 1999).
Since intensity of cytoplasmic immunohistochemical staining
was high in all cases but one, valid statistical correlations with
target gene expression were not feasible. Nuclear immunohisto-
chemical staining was scored as ‘positive’ in seven and ‘negative’ in
four cases. Nuclear positivity was associated with slightly higher
mean mRNA expression levels of BCL2L1 (DCt 1.55 vs 1.75) and
CCND1 (DCt 2.75 vs 2.97), but not of CCND2 (DCt 1.64 vs 1.06) and
NFKBIA (DCt  1.91 vs  1.56). None of these differences reached
statistical significance. Since evaluation of nuclear positivity can be
difficult to determine and statistics were compromised due to the
small sample size and the fact that one variable was nominally
scaled, we hitherto decided to correlate RELA expression levels
with NF-kB target gene expression.
Higher RELA gene expression was statistically significantly
associated with higher NFKBIA (r
2¼0.4816, Po0.05, Figure 3A)
and CCND2 expression levels (r
2¼0.5225, Po0.05, Figure 3B).
Moreover, trends for a correlated expression of RELA and BCL2L1
as well as CCND1 could be observed, but failed to reach statistical
significance (r
2¼0.1504, P40.05 and r
2¼0.2468, P40.05, respec-
tively, Figure 3C). Considering that the expression of NFKBIA was
linked with RELA expression, we sought to countercheck the
observed relationships by correlating the expression of NFKBIA
with other NF-kB target genes. Interestingly, the expression of
NFKBIA and the expression of CCND2 and BCL2L1 were
associated in a statistically significant manner (r
2¼0.7096,
Po0.01 and r
2¼0.4635, Po0.05, respectively, Figure 3D). CCND1
expression was correlated as well, but failed to reach statistical
significance (r
2¼0.4196, P¼0.059, Figure 3D). Thus, high
RELA expression was linked to elevated expression of a number
of NF-kB target genes, first and foremost NFKBIA, arguing for
simultaneous overexpression of RELA and an activation of the
NF-kB pathway. However, the small sample size did not permit
to obtain statistically significant correlations for all genes
investigated.
Table 2 Patient survival in dependence of several clinicopathological
factors and cytoplasmic/nuclear RelA expression
Cases Events
Median
survival
(months)
Standard
error
Log-rank
test
(P-values)
Age at diagnosis (years)
p65 42 34 12.0 1.9 0.229
465 40 31 17.7 2.0
Tumour stage
T1/T2 31 26 16.3 2.9 0.895
T3/T4 51 39 13.3 3.1
Nodal status
N0 26 16 16.3 5.9 0.052
N1 56 49 13.1 1.6
Grade
G1/G2 51 37 18.0 1.5 0.015
G3 31 28 10.1 2.6
RelA cytoplasmic
Negative 40 26 16.3 6.9 0.034
Positive 42 39 13.3 1.9
RelA cytoplasmic (node negative)
Negative 17 7 Not
reached
— 0.005
Positive 9 9 12.0 2.7
RelA nuclear
Negative 45 29 17.7 4.4 0.013
Positive 37 36 13.1 1.8
RelA nuclear (node negative)
Negative 18 8 Not
reached
— 0.023
Positive 8 8 10.1 2.8
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sDISCUSSION
Nuclear factor-kB is centrally involved in tumorigenesis and
tumour progression in various types of cancer. Here, we found the
NF-kB subunit RelA to be overexpressed in roughly half of a large
set of pancreatic adenocarcinomas analysed. Overexpression of
cytoplasmic and/or nuclear RelA in tumour tissue has been
previously observed in larger study cohorts of gastric (Sasaki et al,
2001; Yamanaka et al, 2004; Cao et al, 2005; Lee et al, 2005),
prostate (Fradet et al, 2004; Ismail et al, 2004; Ross et al, 2004;
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Figure 2 Kaplan–Meier survival curves in dependence of clinicopathological factors and RelA/p65 expression patterns. Overall survival dependent on
nodal status (A) and grade (B). Overall survival dependent on cytoplasmic (C and E) and nuclear (D and F) RelA overexpression for the whole study
cohort (C and D) as well as for the subgroup of node-negative patients (E and F).
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sShukla et al, 2004; Sweeney et al, 2004), endometrial (Pallares et al,
2004), hepatocellular (Tai et al, 2000) and oral (Nakayama et al,
2001) as well as cervical (Nair et al, 2003) carcinoma.
Reports on RelA expression in pancreatic cancer are sparse. In
one study, Vimalachandran et al (2005) reported nuclear positivity
for RelA in 23 out of 40 (57%) pancreatic cancers as detected
by immunohistochemistry on tissue microarrays with an antibody
directed against activated RelA. This percentage matches our
results on nuclear protein expression in carcinomas. However, the
authors also observed relevant cytoplasmic expression of ‘acti-
vated’ RelA in benign ducts, a finding we could not confirm.
We observed high cytoplasmic RelA expression in 42 out of 82
cases, and high nuclear RelA expression in 37 out of 82 cases, with
30 cases staining positive in both subcellular localisations and 33
cases being completely negative. Thus, cytoplasmic RelA over-
expression in 81.1% of the cases was associated with nuclear
positivity. One may speculate that cytoplasmic RelA overexpres-
sion is frequently and regularly accompanied by enhanced nuclear
translocation and that only due to limitations of the immuno-
histochemical method nuclear translocation could not be seen in
all cases. We assume that the very good correlations seen for
cytoplasmic RelA expression indicate that it might be an even
better ‘indirect’ marker for nuclear RelA amount than nuclear
positivity, which is sometimes difficult to determine, itself.
However, as translocation of RelA into the nucleus is a required
step in the NF-kB activation cascade, the nuclear localisation that
was evident in 45.1% of cases can be seen as a first sign of NF-kB
activation. Such NF-kB activation in tissue of pancreatic adeno-
carcinomas was previously noted by Wang et al (1999) and Liptay
et al (2003). Wang et al (1999) observed constitutive activation of
NF-kB signaling in 14 out of 20 pancreatic adenocarcinomas and
in 9 of 11 human pancreatic tumour cell lines. In contrast,
Chandler et al (2004) could not unambiguously correlate over-
expression of RelA with activation of NF-kB signaling in two
pancreatic adenocarcinoma cell lines. We show here that increased
expression of RELA was correlated with higher levels of NF-kB
target gene expression, indicative of an activation of the NF-kB
pathway in vivo. Also, this report is the first to describe a method
to reliably measure NF-kB activation in archival tumour tissue.
Important NF-kB target genes in cancer comprise antiapoptotic
genes (Barkett and Gilmore, 1999), genes involved in angiogenesis
(Aggarwal, 2004), and genes involved in the determination of
invasiveness and the potential to metastasise (Fujioka et al,
2003a,b). Consequently, NF-kB inhibition by transfection with a
mutated IkBa leads to a repression of tumorigenic potential
(Fujioka et al, 2003b), angiogenesis (Xiong et al, 2004) and
metastatic potential (Fujioka et al, 2003a) of pancreatic adeno-
carcinoma cell lines in xenograft mouse models.
The cause of NF-kB activation in pancreatic adenocarcinomas is
the focus of intense investigative efforts (Sclabas et al, 2003). It is
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Figure 3 Correlation of RELA expression with NF-kB target gene expression. Higher levels of RELA expression, as indicated by decreasing DCt values,
were significantly associated with higher expression of (A) NFKBIA (r
2¼0.4816, Po0.05) and (B) CCND2 (r
2¼0.5225, Po0.05). (C) A trend that higher
expression levels of CCND1 (circles) and BCL2L1 (squares) correlated with higher RELA expression levels was observed as well. (D) NFKBIA expression
correlated positively with CCND2 (squares, r
2¼0.7096, Po0.01), BCL2L1 (closed circles, r
2¼0.4635, Po0.05) and CCND1 (open circles, r
2¼0.4196,
P¼0.059) expression (see text).
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sconceivable that K-Ras mutations, which are frequently present in
pancreatic adenocarcinomas (Hruban et al, 1993) lead to an
activation of NF-kB transcriptional activity (Finco et al, 1997).
Alternatively, NF-kB might be induced via EGFR-mediated path-
ways, since EGFR was found to be overexpressed in 30–50% of
pancreatic adenocarcinomas (Korc et al, 1986), and EGFR
activation was proposed to lead to NF-kB activation in cell lines
(Habib et al, 2001).
The actual reasons for the overexpression of RelA in pancreatic
cancer are not clear. Our data hint at enhanced transcriptional
activity, as RelA protein expression is paralleled by enhanced
mRNA expression. The deregulation of RelA might be caused by
altered intracellular signal transduction or chromosomal over-
representation of the respective gene locus. And in fact RELA
amplification has been described in various solid tumours (Rayet
and Gelinas, 1999), but not in ductal pancreatic adenocarcinomas
(Schleger et al, 2000).
Patients with RelA-positive tumours had a significantly shortened
overall survival. This observation was even more pronounced in the
clinically important subgroup of nodal-negative patients, potentially
amenable for curative surgical treatment. However, owing to the
small case numbers in this subgroup analysis, these results need to
be confirmed in a larger study cohort before draw any final
conclusions. An unavoidable limitation of our study is that only
patients with resectable tumours were included. Thus, it is not
finally clear whether our results apply to patients with advanced
non-resectable pancreatic carcinomas, as well.
Still, these findings may help to individualise treatment and to
identify patients, which may profit exceptionally from NF-kB-
blocking agents.
The prognostic value of RelA is in concordance with studies on
prostate cancer, in which both nuclear and cytoplasmic RelA
overexpression were linked to disease progression (Fradet et al,
2004; Ross et al, 2004). In gastric adenocarcinoma, the prognostic
impact of RelA expression appears to be somewhat conflictive, as
overexpression was reported both to be an indicator of adverse
(Sasaki et al, 2001; Yamanaka et al, 2004) and favourable (Lee et al,
2005) patient prognosis.
This study provides the missing translational link for the
accumulating evidence obtained from small sets of tumour
samples and from functional studies in tumour cell lines that
NF-kB activation plays a prominent role in pancreatic cancer
development and progression. This is further emphasised by the
suggestion of a hitherto unreported link between overexpression of
an NF-kB subunit and NF-kB activation, and should lead to
increased efforts for the development and use of NF-kB inhibitory
drugs to treat pancreatic cancer.
Importantly, the description of a significant prognostic marker
is exceedingly rare in pancreatic cancer. The observation that
patients overexpressing RelA show a dramatically decreased
survival time may allow stratifying patients into two subgroups:
one subgroup is likely to benefit from NF-kB-inhibiting agents and
another subgroup which has a relatively good survival perspective
irrespective of such a treatment, potentially because resistance to
conventional chemotherapeutics due to NF-kB activation has not
occurred yet (Arlt et al, 2001, 2003). This possibility should be
considered when clinical trials with NF-kB-inhibiting agents are
being planned.
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